Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel — Update
A
Angela Yen
(Vertex Pharmaceuticals, Boston)
T
Tony Boitano
(Vertex Pharmaceuticals, Boston)
Z
Zachary Zappala
(Vertex Pharmaceuticals, Boston)
S
Sudipta Mahajan
(Vertex Pharmaceuticals, Boston)
T
Thomas Willems
(Vertex Pharmaceuticals, Boston)
T
Timothy D. Majarian
(Vertex Pharmaceuticals, Boston)
P
Preethi Thunga
(Vertex Pharmaceuticals, Boston)
D
David Altshuler
(Vertex Pharmaceuticals, Boston)
Article Details
Journal
New England Journal of Medicine
Volume / Issue
Vol. 393, Issue 14
Published
October 09, 2025
Pages
1440-1442
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Journal Info
New England Journal of Medicine
Massachusetts Medical Society
ISSN: 0028-4793 Social Sciences
Authors (8)
A
Angela Yen
Vertex Pharmaceuticals, Boston
T
Tony Boitano
Vertex Pharmaceuticals, Boston
Z
Zachary Zappala
Vertex Pharmaceuticals, Boston
S
Sudipta Mahajan
Vertex Pharmaceuticals, Boston
T
Thomas Willems
Vertex Pharmaceuticals, Boston
T
Timothy D. Majarian
Vertex Pharmaceuticals, Boston
P
Preethi Thunga
Vertex Pharmaceuticals, Boston
D
David Altshuler
Vertex Pharmaceuticals, Boston
Related Articles from this Journal
Doctor’s Dirty Little Secret — The Cost of Silence
Tara Khan
Aug 2026
10.1056/nejmp2515506
Obstructive Hypertrophic Cardiomyopathy
Julian-Kai Nishizono, Marohito Nakata
Aug 2026
10.1056/nejmicm2603868
T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation
Martina Schatzl, Katharina A. Mayer et al.
Jul 2026
10.1056/nejmc2603853
Products That Pose Health Risks — Can Litigation Protect Us When Government Fails?
Jerry Avorn
Jul 2026
10.1056/nejmp2604841
Precision Intensification in Metastatic Prostate Cancer
Rana R. McKay
Jul 2026
10.1056/nejme2605582